Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631601 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT04631601 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 65 participants.
The verdict
NCT04631601, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG AMG 404
- DRUG Acapatamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2023-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631601
The ClinicalTrials.gov registry entry for NCT04631601 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Enzalutamide is the first listed.
NCT04631601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04631601 about?
NCT04631601 is a clinical study titled "Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)". This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
What is the current status of trial NCT04631601?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2021-01-15. Estimated completion is 2023-10-23.
What interventions are being tested in trial NCT04631601?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone (DRUG), AMG 404 (DRUG), Acapatamab (DRUG).
Who is sponsoring clinical trial NCT04631601?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.